
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-07-05-2017
- Volume 12
- Issue 7
FUJIFILM Announces Completion of 100th Program Using Protein Expression System
The company announced that it has completed its 100th program using the pAVEway protein expression system, which was originally introduced to the market in 2007.
On June 20, 2017, FUJIFILM Diosynth Biotechnologies announced the completion of its 100th program using pAVEway Advanced Protein Expression system. The expression system was originally introduced to the market during the 2007 BIO International Convention in Boston, Massachusetts.
pAVEway was developed by FUJIFILM Diosynth Biotechnologies to enable the reliable and scalable GMP manufacturing of E.coli -based processes. The pAVEway system has the ability to control protein expression by allowing expression and secretion to be coupled. It also allows for slower expression, which can result in a higher chance of folding, and to sustain accumulation for many hours with continued cell growth. The system is suited to investigate difficult-to-express proteins with protein toxicity to the cells.
Source: FUJIFILM
Articles in this issue
over 8 years ago
Overcoming Concerns to Adopting Continuous Processesover 8 years ago
The Search for Efficient Synthesis of Complex Cannabinoidsover 8 years ago
BASF Ups Ibuprofen Capacities in Germany and North Americaover 8 years ago
Itzhak Krinsky Joins Halo Pharma Board of Directorsover 8 years ago
Survey Reveals that Blockchain will be Adopted Within Five Yearsover 8 years ago
Agilent Adds Products to InfinityLab LC SeriesNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





